More news
-
NewsEli Lilly bets $2.8bn on AtaiBeckley’s psychedelic therapies for depression
AtaiBeckley’s lead asset addresses synaptic connectivity rather than neurotransmitter levels, as targeted by traditional antidepressants.
-
NewsPh. Eur. revises general chapter on alternative microbiological methods
The updated general chapter 5.1.6 provides a modernised text intended to streamline implementation for users.
-
NewsSandoz reshapes leadership to capitalise on biosimilar golden decade
New appointments will drive manufacturing efficiency in Sandoz’s generics business and merger and acquisition activities globally.
-
NewsAstraZeneca licenses novel oral EGFR inhibitor for $1.5bn
Agreement with Dizal Pharmaceutical gives the pharmaceutical giant access to the only approved oral targeted therapy for EGFR exon 20 insertion NSCLC in both the US and China.
-
NewsNovel vaccine framework illustrates promise for oral cancer vaccines
Genetically modified Bifidobacterium could enhance patient response to immune checkpoint inhibitors, new clinical data suggests.
-
NewsFDA presents route to improve operational efficiency of drug manufacturing
Proposal aims to modernise registration for distributed drug manufacturers, strengthening real-time transparency across the pharmaceutical supply chain.
-
NewsEvonik invests $100m to modernise Indiana API facility
The move strengthens Evonik’s capabilities to manufacture increasing complex APIs at its site in Lafayette, Indiana.
-
NewsVertex acquires Crinetics in $10bn endocrinology deal
Acquisition set to bolster Vertex’s rare disease portfolio with addition of two potentially best-in-class endocrine assets.
-
NewsStudy illustrates alternative to cold chain storage for mRNA vaccines
Research advances dry mRNA vaccine microneedle patch design, potentially improving storage and distribution of these types of vaccines.
-
NewsAbbVie’s epcoritamab combination approved as first bispecific therapy for follicular lymphoma in EU
European Commission’s approval brings a chemotherapy-free option to patients and develops AbbVie’s oncology and antibody portfolio.
-
NewsEDQM opens consultation on new revised draft Ph. Eur. monographs
CEP holders are invited to submit feedback on draft monographs for fifteen substances.
-
NewsIpsen strengthens rare disease pipeline with €700m acquisition of Memo Therapeutics
Deal involves potential first-in-class BK polyomavirus monoclonal antibody as potential breakthrough therapy in kidney transplantation.
-
NewsUS approval of Orca’s Tregzi landmark advance for stem cell transplants
FDA’s authorisation based on data showing the precision-engineered cell therapy improved survival free of GVHD in adults with haematological malignancies.
-
NewsLonza expands manufacturing capacity for HPAPI and ADC payload-linkers
Investment at Lonza’s facility in Visp, Switzerland designed to meet increasing demand in the ADC market.
-
NewsSimplified C-glycosides synthesis could transform diabetes drug manufacturing
The two-step synthesis process offers a streamlined approach that removes longstanding barriers to scalable C-glycoside manufacture for SGLT2 inhibitors.
-
NewsPredictive stability modelling could optimise moisture-sensitive formulations
Research provides a data-driven foundation for excipient selection in drug formulation development, particularly solid dosage forms.
-
NewsGenentech’s Xofluza approved as first single-dose generic for influenza in US
FDA’s approval of generic baloxavir marboxil tablets for influenza broads access to a novel-mechanism antiviral for individuals aged five years and over.
-
NewsNovartis and Antares target undruggable oncology in $1.8bn deal
Agreement underlines growing investment in next-generation discovery platforms as pharma companies seek differentiated mechanisms of action in an increasingly competitive oncology landscape.
-
NewsEDQM removes rabbit pyrogen test references in revised OCABR guidelines
Guideline revisions support the EU’s ongoing transition away from using animals for in vivo testing of parenteral medicines.
-
NewsCARsgen wins first global approval of CAR T therapy for solid tumours
Approval of the autologous cell therapy satri-cel in China fills the gap in later-line treatment for advanced gastric cancer.